ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Mycobacterium Infections, Nontuberculous

Conditions

Mycobacterium Infections, Nontuberculous

Trial Timeline

Apr 1, 2021 → Jan 15, 2026

NCT ID

NCT04677569

About ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)

ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS) is a phase 3 stage product being developed by Insmed for Mycobacterium Infections, Nontuberculous. The current trial status is completed. This product is registered under clinical trial identifier NCT04677569. Target conditions include Mycobacterium Infections, Nontuberculous.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04677569	Phase 3	Completed	Apr 1, 2021	Jan 15, 2026	Mycobacterium Infections, Nontuberculous

Competing Products

20 competing products in Mycobacterium Infections, Nontuberculous

See all competitors

Product	Company	Stage	Hype Score
Trifluridine	Amgen	Pre-clinical	22
clarithromycin, rifabutin	Pfizer	Approved	84
Azithromycin	Pfizer	Pre-clinical	22
Ethambutol hydrochloride + Clarithromycin + Azithromycin	Pfizer	Phase 3	76
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Pre-clinical	22
Azithromycin	Pfizer	Approved	84
Tigecycline	Pfizer	Phase 2	51
Azithromycin + Rifabutin/rifampin	Pfizer	Approved	84
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	74
LAI plus multi-drug regimen	Insmed	Phase 2	49
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	49
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	74
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + Rifabutin	Innoviva	Phase 2	47
Molgramostim nebulizer solution	Savara	Phase 2	47
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	47
Epetraborole + Epetraborole + Placebo + Placebo	AN2 Therapeutics	Phase 2	44
SPR720 + Placebo + Open-label Standard of Care	Spero Therapeutics	Phase 2	44
RHB-204 + Placebo	RedHill Biopharma	Phase 3	69

Other Products from Insmed

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.Phase 3

Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3

ALIS + Azithromycin + Ethambutol + ELCPhase 3

LAI 590 mg + Multi-drug regimenPhase 3